1. Home
  2. Clinical Topics
  3. FDA allows marketing of device to help assess children and teens for ADHD
Clinical TopicsDrugs and DevicesHealthcare & TechnologyNeurologyNewsPediatricsWeb Exclusives

FDA allows marketing of device to help assess children and teens for ADHD

Share

On June 15, the U.S. Food and Drug Administration (FDA) allowed marketing of the first medical device based on brain function to help assess attention-deficit/hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old. The Neuropsychiatric EEG-Based Assessment Aid (NEBA) System is a 15- to 20-minute noninvasive test that calculates the ratio of theta and beta waves. The theta/beta ratio has been shown to be higher in children and adolescents with ADHD. Read more.

Leave a Reply

Your email address will not be published.

Fill out this field
Fill out this field
Please enter a valid email address.

Get your free subscription to NurseLine!

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.

Recent Posts